Recent developments in antiretroviral therapies

[41] Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217 [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1999, 10 (06) : 315 - 320

[42] S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1 [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) : 1340 - 1345

[43] Structure based design:: Novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (08) : 979 - 982

[44] Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (06) : 687 - 690

[45] Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) : 13040 - 13043

[46] Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane [J]. NUCLEOSIDES & NUCLEOTIDES, 1999, 18 (4-5): : 891 - 892

[47] Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2376 - 2382

[48] GULICK R, 2000, 7 C RETR OPP INF

[49] HAMMOND J, 1999, 6 C RETR OPP INF

[50] A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition [J]. BIOCHEMISTRY, 1998, 37 (15) : 5086 - 5095

[41] Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217 [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1999, 10 (06) : 315 - 320

[42] S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1 [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) : 1340 - 1345

[43] Structure based design:: Novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (08) : 979 - 982

[44] Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (06) : 687 - 690

[45] Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) : 13040 - 13043

[46] Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane [J]. NUCLEOSIDES & NUCLEOTIDES, 1999, 18 (4-5): : 891 - 892

[47] Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2376 - 2382

[48] GULICK R, 2000, 7 C RETR OPP INF

[49] HAMMOND J, 1999, 6 C RETR OPP INF

[50] A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition [J]. BIOCHEMISTRY, 1998, 37 (15) : 5086 - 5095